Item 1A. Risk Factors
3K characters. Original on sec.gov · Markdown
Item 1A. Risk Factors
There have been no material changes to the risk factors previously disclosed in Item 1A., "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2021.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Conversion of Certain Convertible Notes
In June 2022, we received notices from holders of the Convertible Notes requesting the conversion of the aggregate principal of Convertible Notes stated in the table below (the Converted Notes). We settled the conversion of the Converted Notes by issuing to the converting holders of the Converted Notes shares of EQT common stock. Such shares were issued in transactions exempt from registration under the Securities Act by virtue of Section 3(a)(9) thereof, because no commission or other remuneration was paid in connection with conversion of the Converted Notes.
| Settlement Date | Principal Converted | Shares Issued | Fair Market Value | |||||||||||||||||
| (Thousands) | (Thousands) | |||||||||||||||||||
| July 1, 2022 | $ | 3 | 201 | $ | 7 | |||||||||||||||
| July 5, 2022 | 2 | 134 | 5 |
Repurchases of Equity Securities
We did not repurchase any equity securities registered under Section 12 of the Exchange Act during the three months ended June 30, 2022.
On December 13, 2021, we announced that our Board of Directors approved a share repurchase program to repurchase shares of our outstanding common stock for an aggregate purchase price of up to $1 billion, excluding fees, commissions and expenses. Pursuant to the share repurchase authority, we may repurchase shares from time to time in the open market or in privately negotiated transactions. The share repurchase authority does not obligate us to acquire any specific number of shares, was effective immediately and is valid through December 31, 2023. We did not repurchase any shares pursuant to the share repurchase authority during the three months ended June 30, 2022. As of June 30, 2022, we had purchased shares for an aggregate purchase price of $229.2 million, excluding fees, commissions and expenses, under this authorization since its inception.
Previous: Item 4. Controls and Procedures · Next: Item 6. Exhibits